Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor

Lior Zilberberg, Svetlana Shinkaruk, Olivier Lequin, Benoit Rousseau, Martin Hagedorn, Francesco Costa, Dario Caronzolo, Maurice Balke, Xavier Canron, Odile Convert, Georges Laïn, Karine Gionnet, Mario Gonçalvès, Mireille Bayle, Lorenzo Bello, Gerard Chassaing, Gérard Deleris, Andreas Bikfalvi

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Blocking angiogenesis is an attractive strategy to inhibit tumor growth, invasion, and metastasis. We describe here the structure and the biological action of a new cyclic peptide derived from vascular endothelial growth factor (VEGF). This 17-amino acid molecule designated cyclopeptidic vascular endothelial growth inhibitor (cyclo-VEGI, CBO-P11) encompasses residues 79-93 of VEGF which are involved in the interaction with VEGF receptor-2. In aqueous solution, cyclo-VEGI presents a propensity to adopt a helix conformation that was largely unexpected because only β-sheet structures or random coil conformations have been observed for macrocyclic peptides. Cyclo-VEGI inhibits binding of iodinated VEGF165 to endothelial cells, endothelial cells proliferation, migration, and signaling induced by VEGF165. This peptide also exhibits anti-angiogenic activity in vivo on the differentiated chicken chorioallantoic membrane. Furthermore, cyclo-VEGI significantly blocks the growth of established intracranial glioma in nude and syngeneic mice and improves survival without side effects. Taken together, these results suggest that cyclo-VEGI is an attractive candidate for the development of novel angiogenesis inhibitor molecules useful for the treatment of cancer and other angiogenesis-related diseases.

Original languageEnglish
Pages (from-to)35564-35573
Number of pages10
JournalJournal of Biological Chemistry
Volume278
Issue number37
DOIs
Publication statusPublished - Sep 12 2003

Fingerprint

Growth Inhibitors
Blood Vessels
Tumors
Neoplasms
Endothelial cells
Vascular Endothelial Growth Factor A
Conformations
Endothelial Cells
Chorioallantoic Membrane
Vascular Endothelial Growth Factor Receptor-2
Cyclic Peptides
Peptides
Molecules
Angiogenesis Inhibitors
Cell proliferation
Growth
Nude Mice
Glioma
Cell Movement
cyclo-VEGI

ASJC Scopus subject areas

  • Biochemistry

Cite this

Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. / Zilberberg, Lior; Shinkaruk, Svetlana; Lequin, Olivier; Rousseau, Benoit; Hagedorn, Martin; Costa, Francesco; Caronzolo, Dario; Balke, Maurice; Canron, Xavier; Convert, Odile; Laïn, Georges; Gionnet, Karine; Gonçalvès, Mario; Bayle, Mireille; Bello, Lorenzo; Chassaing, Gerard; Deleris, Gérard; Bikfalvi, Andreas.

In: Journal of Biological Chemistry, Vol. 278, No. 37, 12.09.2003, p. 35564-35573.

Research output: Contribution to journalArticle

Zilberberg, L, Shinkaruk, S, Lequin, O, Rousseau, B, Hagedorn, M, Costa, F, Caronzolo, D, Balke, M, Canron, X, Convert, O, Laïn, G, Gionnet, K, Gonçalvès, M, Bayle, M, Bello, L, Chassaing, G, Deleris, G & Bikfalvi, A 2003, 'Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor', Journal of Biological Chemistry, vol. 278, no. 37, pp. 35564-35573. https://doi.org/10.1074/jbc.M304435200
Zilberberg, Lior ; Shinkaruk, Svetlana ; Lequin, Olivier ; Rousseau, Benoit ; Hagedorn, Martin ; Costa, Francesco ; Caronzolo, Dario ; Balke, Maurice ; Canron, Xavier ; Convert, Odile ; Laïn, Georges ; Gionnet, Karine ; Gonçalvès, Mario ; Bayle, Mireille ; Bello, Lorenzo ; Chassaing, Gerard ; Deleris, Gérard ; Bikfalvi, Andreas. / Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. In: Journal of Biological Chemistry. 2003 ; Vol. 278, No. 37. pp. 35564-35573.
@article{1cb65ecab1b34526945ea9600181ff7b,
title = "Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor",
abstract = "Blocking angiogenesis is an attractive strategy to inhibit tumor growth, invasion, and metastasis. We describe here the structure and the biological action of a new cyclic peptide derived from vascular endothelial growth factor (VEGF). This 17-amino acid molecule designated cyclopeptidic vascular endothelial growth inhibitor (cyclo-VEGI, CBO-P11) encompasses residues 79-93 of VEGF which are involved in the interaction with VEGF receptor-2. In aqueous solution, cyclo-VEGI presents a propensity to adopt a helix conformation that was largely unexpected because only β-sheet structures or random coil conformations have been observed for macrocyclic peptides. Cyclo-VEGI inhibits binding of iodinated VEGF165 to endothelial cells, endothelial cells proliferation, migration, and signaling induced by VEGF165. This peptide also exhibits anti-angiogenic activity in vivo on the differentiated chicken chorioallantoic membrane. Furthermore, cyclo-VEGI significantly blocks the growth of established intracranial glioma in nude and syngeneic mice and improves survival without side effects. Taken together, these results suggest that cyclo-VEGI is an attractive candidate for the development of novel angiogenesis inhibitor molecules useful for the treatment of cancer and other angiogenesis-related diseases.",
author = "Lior Zilberberg and Svetlana Shinkaruk and Olivier Lequin and Benoit Rousseau and Martin Hagedorn and Francesco Costa and Dario Caronzolo and Maurice Balke and Xavier Canron and Odile Convert and Georges La{\"i}n and Karine Gionnet and Mario Gon{\cc}alv{\`e}s and Mireille Bayle and Lorenzo Bello and Gerard Chassaing and G{\'e}rard Deleris and Andreas Bikfalvi",
year = "2003",
month = "9",
day = "12",
doi = "10.1074/jbc.M304435200",
language = "English",
volume = "278",
pages = "35564--35573",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "37",

}

TY - JOUR

T1 - Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor

AU - Zilberberg, Lior

AU - Shinkaruk, Svetlana

AU - Lequin, Olivier

AU - Rousseau, Benoit

AU - Hagedorn, Martin

AU - Costa, Francesco

AU - Caronzolo, Dario

AU - Balke, Maurice

AU - Canron, Xavier

AU - Convert, Odile

AU - Laïn, Georges

AU - Gionnet, Karine

AU - Gonçalvès, Mario

AU - Bayle, Mireille

AU - Bello, Lorenzo

AU - Chassaing, Gerard

AU - Deleris, Gérard

AU - Bikfalvi, Andreas

PY - 2003/9/12

Y1 - 2003/9/12

N2 - Blocking angiogenesis is an attractive strategy to inhibit tumor growth, invasion, and metastasis. We describe here the structure and the biological action of a new cyclic peptide derived from vascular endothelial growth factor (VEGF). This 17-amino acid molecule designated cyclopeptidic vascular endothelial growth inhibitor (cyclo-VEGI, CBO-P11) encompasses residues 79-93 of VEGF which are involved in the interaction with VEGF receptor-2. In aqueous solution, cyclo-VEGI presents a propensity to adopt a helix conformation that was largely unexpected because only β-sheet structures or random coil conformations have been observed for macrocyclic peptides. Cyclo-VEGI inhibits binding of iodinated VEGF165 to endothelial cells, endothelial cells proliferation, migration, and signaling induced by VEGF165. This peptide also exhibits anti-angiogenic activity in vivo on the differentiated chicken chorioallantoic membrane. Furthermore, cyclo-VEGI significantly blocks the growth of established intracranial glioma in nude and syngeneic mice and improves survival without side effects. Taken together, these results suggest that cyclo-VEGI is an attractive candidate for the development of novel angiogenesis inhibitor molecules useful for the treatment of cancer and other angiogenesis-related diseases.

AB - Blocking angiogenesis is an attractive strategy to inhibit tumor growth, invasion, and metastasis. We describe here the structure and the biological action of a new cyclic peptide derived from vascular endothelial growth factor (VEGF). This 17-amino acid molecule designated cyclopeptidic vascular endothelial growth inhibitor (cyclo-VEGI, CBO-P11) encompasses residues 79-93 of VEGF which are involved in the interaction with VEGF receptor-2. In aqueous solution, cyclo-VEGI presents a propensity to adopt a helix conformation that was largely unexpected because only β-sheet structures or random coil conformations have been observed for macrocyclic peptides. Cyclo-VEGI inhibits binding of iodinated VEGF165 to endothelial cells, endothelial cells proliferation, migration, and signaling induced by VEGF165. This peptide also exhibits anti-angiogenic activity in vivo on the differentiated chicken chorioallantoic membrane. Furthermore, cyclo-VEGI significantly blocks the growth of established intracranial glioma in nude and syngeneic mice and improves survival without side effects. Taken together, these results suggest that cyclo-VEGI is an attractive candidate for the development of novel angiogenesis inhibitor molecules useful for the treatment of cancer and other angiogenesis-related diseases.

UR - http://www.scopus.com/inward/record.url?scp=0042817965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042817965&partnerID=8YFLogxK

U2 - 10.1074/jbc.M304435200

DO - 10.1074/jbc.M304435200

M3 - Article

C2 - 12837752

AN - SCOPUS:0042817965

VL - 278

SP - 35564

EP - 35573

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 37

ER -